In vivo experiments demonstrate improved healing rates and pain relief using a microneedle patch in diabetic wounds, suggesting better treatment options.
Wound-associated pain is often underestimated and undertreated, especially in chronic wounds, which is becoming a potential threat to public health. However, limited strategies for both wound healing and analgesia remain an ongoing challenge in clinical applications. Herein, a spatial-efficacy microneedle patch with amplified immunomodulation targeting healing and analgesia during wound care is proposed. The ibuprofen (Ib) loaded microneedle patch (Ib-MNs) is synthesized by crosslinking two immunologically active natural polysaccharides. The tip structure endows the Ib-MNs with rapid deep-wound access, and a drug delivery depth that surpassed hydrogels by up to 5-fold. Moreover, the presence of dual immunologically active components significantly enhances the immune regulatory effects, promoting polarization toward M2-type macrophages. Furthermore, in vivo experiments validated that immune regulation ensured pro-healing conditions, achieving a healing rate of 94.6% by day 14. The Ib-MNs effectively increased the mechanical stimulation threshold for wound pain by 2.6-fold compared to the commercial 3 m Tegaderm dressing on the first day and demonstrated sustained analgesic effects during the healing process. This dressing, designed for compassionate care of patients with wound-related pain, suggests a promising and facile therapeutic strategy for personalized wound management in clinical practice.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: